title: Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for 'middle'?
authors: Masaru
authors: M
authors: Enomoto
authors: Akihiro
authors: A
authors: Tamori
authors: Sawako
authors: S
authors: Kobayashi
authors: Shuji
authors: S
authors: Iwai
authors: Hiroyasu
authors: H
authors: Morikawa
authors: Norifumi
authors: N
authors: Kawada
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D009842:Oligopeptides / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000627:therapeutic use*
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D011480:Protease Inhibitors
references: Hepatol Res. 2010 Jan;40(1):8-13
references: 20156296
references: J Gastroenterol. 2013 Jan;48(1):1-12
references: 23188091
references: J Hepatol. 2012 Jan;56(1):78-84
references: 21827730
references: Nat Genet. 2009 Oct;41(10):1105-9
references: 19749757
references: Hepatology. 2011 Oct;54(4):1433-44
references: 21898493
references: Hepatology. 2009 Apr;49(4):1335-74
references: 19330875